 |
Press Releases
SAN DIEGO, June 26, 2009 – CareFusion Corporation, the company that will become public from the planned spinoff of Cardinal Health’s clinical and medical products businesses, today announced that Robert Friel will serve on the company’s board of directors following the completion of the spinoff.
Friel, 53, is chairman and chief executive officer of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment. He joined PerkinElmer in 1999 and has served in a variety of roles including chief financial officer, chief operating officer and divisional president.
The company made the announcement in the third amendment to its Form 10 registration statement, filed today with the Securities and Exchange Commission (SEC).
Friel joins CareFusion board members announced on June 9, including David Schlotterbeck, 62, chairman and chief executive officer; Philip Francis, 61, executive chairman of PetSmart, Inc. and Cardinal Health director since 2006; Jacqueline Kosecoff, 59, chief executive officer of Prescription Solutions for UnitedHealth Group; J. Michael Losh, 63, retired chief financial officer of General Motors and Cardinal Health director since 1996; Gregory Lucier, 45, chairman and chief executive officer of Life Technologies; Edward Miller, M.D., 66, chief executive officer of Johns Hopkins Medicine; Michael O’Halleran, 58, senior executive vice president of Aon Corporation and Cardinal Health director since 1999; and Robert Wayman, 63, retired executive vice president and chief financial officer of Hewlett Packard. Francis, Losh and O’Halleran will leave the Cardinal Health board of directors upon completion of the planned spinoff.
About CareFusion Corporation
CareFusion Corporation is currently a wholly owned subsidiary of Cardinal Health (NYSE:CAH) and is expected to become a public company from the planned spinoff of Cardinal Health’s clinical and medical products businesses. The global company, with annual revenues of approximately $3.8 billion1, will serve the health care industry with products and services that help hospitals improve the safety and quality of health care. With a focus on breaking the cycle of harmful medication errors and reducing hospital-acquired infections, CareFusion develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, MedMined™ electronic infection surveillance service, AVEA and Pulmonetic Systems ventilation and respiratory products, Jaeger and SensorMedics pulmonary products, ChloraPrep® infection prevention products and V. Mueller® surgical instruments. CareFusion employs more than 15,000 people across its global operations. The company has applied to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol “CFN.”
1 Fiscal 2008 pro forma revenue, Amendment No. 3 to Form 10 Registration Statement filed on June 26, 2009.
Cautions Concerning Forward-Looking Statements
This news release contains forward-looking statements addressing the planned spinoff of Cardinal Health’s clinical and medical products businesses as a separate company named CareFusion, which is dependent upon future events or developments and subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include uncertainties regarding the planned spinoff of CareFusion, including the timing and terms of any such spinoff and whether such spinoff will be completed as it is subject to a number of conditions. In addition, Cardinal Health and CareFusion are subject to additional risks and uncertainties described in CareFusion’s Form 10 and Cardinal Health’s Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports. Except to the extent required by applicable law, Cardinal Health and CareFusion undertake no obligation to update or revise any forward-looking statement.
